George Wilding
Overview
Explore the profile of George Wilding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
8843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair S, Muhammad H, Jain P, Xie C, Pavlova I, Brody R, et al.
Eur Urol
. 2024 Sep;
PMID: 39232981
No abstract available.
2.
Li J, Hilimire T, Liu Y, Wang L, Liang J, Gyorffy B, et al.
J Clin Invest
. 2024 Mar;
134(10).
PMID: 38546787
Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition...
3.
Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Oudard S, et al.
J Clin Oncol
. 2023 Apr;
41(11):1965-1971.
PMID: 37018919
Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final...
4.
Krishnamurthy S, Jain P, Tripathy D, Basset R, Randhawa R, Muhammad H, et al.
JCO Clin Cancer Inform
. 2023 Mar;
7:e2200181.
PMID: 36961981
Purpose: Achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved patient outcomes in triple-negative breast cancer (TNBC). Currently, there are no validated predictive biomarkers for...
5.
Huang W, Randhawa R, Jain P, Hubbard S, Eickhoff J, Kummar S, et al.
JCO Clin Cancer Inform
. 2022 Feb;
6:e2100131.
PMID: 35192404
Purpose: To develop a novel artificial intelligence (AI)-powered method for the prediction of prostate cancer (PCa) early recurrence and identification of driver regions in PCa of all Gleason Grade Group...
6.
Basu H, Wilganowski N, Robertson S, Reuben J, Cohen E, Zurita A, et al.
Prostate
. 2021 Jun;
81(12):799-811.
PMID: 34170017
Background: Most cancer cells are more glycolytic even under aerobic conditions compared with their normal counterparts. Recent evidence of tumor cell metabolism, however, shows that some tumors also increase mitochondrial...
7.
Joseph J, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, et al.
Bladder Cancer
. 2018 Nov;
4(Suppl 1):S1-S43.
PMID: 30443561
No abstract available.
8.
Wong Y, Manola J, Hudes G, Roth B, Moul J, Barsevick A, et al.
Clin Genitourin Cancer
. 2017 Nov;
16(2):e315-e322.
PMID: 29173976
Introduction: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). Patients And Methods: We enrolled 77 patients who had received...
9.
Engle J, Traynor A, Campbell T, Wisinski K, LoConte N, Liu G, et al.
J Oncol Pharm Pract
. 2017 May;
24(5):348-353.
PMID: 28457192
Background/Aims Oral chemotherapy is increasingly utilized leaving the patient responsible for self-administering an often complex regimen where adverse effects are common. Non-adherence and reduced relative dose intensity are both associated...
10.
Tang C, Sherman S, Price M, Weng J, Davis S, Hong D, et al.
Clin Cancer Res
. 2017 Mar;
23(6):1414-1421.
PMID: 28275168
Slow-accruing clinical trials delay the translation of basic biomedical research, contribute to increasing health care costs, and may prohibit trials from reaching their original goals. We analyzed a prospectively maintained...